-
Mashup Score: 0Hot Topics in ADHD: Expert Poster Presentation Session - 3 year(s) ago
Learn the latest from the 2021 APSARD meeting.
Source: MedscapeCategories: Latest Headlines, PediatricsTweet
-
Mashup Score: 0Hot Topics in ADHD: Expert Poster Presentation Session - 3 year(s) ago
Learn the latest from the 2021 APSARD meeting.
Source: MedscapeCategories: Latest Headlines, PsychiatryTweet-
Hot topics in #ADHD: This expert poster presentation from both #APA2021 and #APSARD2021 explores emerging clinical data and MOAs for new treatment options. https://t.co/CuXgArljVt https://t.co/x9zZq1Tou6
-
-
Mashup Score: 0ADHD - 3 year(s) ago
undefined
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet-
#APSARD2021 Virtual Meeting may have concluded in January, but our #ADHD coverage continues. Check out all of our multimedia content below: https://t.co/kDVaepc6bz
-
-
Mashup Score: 0The Importance of an ADHD-Research Conference: Matthew Brams, MD - 3 year(s) ago
Dr. Matthew Brams presented new data showing the efficacy of CTx-1301 for ADHD.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
Dr. Matthew Brams wraps up the importance of #APSARD2021. https://t.co/wupIzD3r2z
-
-
Mashup Score: 1
HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. At HCPLive, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician…
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet-
Miss anything from #APSARD2021? You can find all the KOL interviews and new #ADHD data on our APSARD conference page! https://t.co/MnXMkfbr5N
-
-
Mashup Score: 1The Value of CTx-1301 for ADHD - 3 year(s) ago
CTx-1301’s formulation enables 3 different doses within 1 pill for ADHD.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
Dr. Matthew Brams talks to @Kenny_Walter31 about CTx-1301, a potential long-lasting #ADHD treatment. #APSARD2021 https://t.co/fRgvC3x908
-
-
Mashup Score: 0CTx-1301 Eliminates Crash in ADHD Patients - 3 year(s) ago
Researchers are prepared a phase 3 trial testing the treatment in adults with ADHD.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
Dr. Matthew Brams talks about CTx-1301 and why it could be a game changer in ADHD. #APSARD2021 https://t.co/n8lYei8CdV
-
-
Mashup Score: 0ADHD Polygenic Risk Scores May Benefit Pediatric Bipolar, Mood Disorder Understanding - 3 year(s) ago
Such scores could provide insight into the significant comorbidity rate of ADHD and other youth mood and emotional dysregulation issues.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
“These finding suggest that #ADHD polygenic risk scores may have the most important contribution to the development of mood related problems in youth and may begin to explain the high comorbidity." #APSARD2021 https://t.co/kWaAG4NDWy
-
-
Mashup Score: 0
Randomized controlled trials are needed to evaluate their efficacy in comparison with in-person group meetings.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
According to new data presented at #APSARD2021, 88% of parents of children with #ADHD reported overall satisfaction with virtual behavioral parent training. https://t.co/25SdcHhVCk
-
-
Mashup Score: 0ADHD Treatment Change Impacts Remote Patient Monitoring - 3 year(s) ago
Personalized, daily self-reporting for patients could influence future therapeutic strategies.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
“We know that #ADHD symptoms respond rapidly to some forms of psychopharmacology as measured on well-validated rating scales. In clinical practice, individuals may find particular symptoms easier to recognize and report on than others.” #APSARD2021 https://t.co/zsZIDfXbtx
-
Hot topics in #ADHD: This expert poster presentation from both #APA2021 and #APSARD2021 explores emerging clinical data and MOAs for new treatment options. https://t.co/zJzTuzuEhh https://t.co/A34hX0EuKs